生物活性 | |||
---|---|---|---|
描述 | Enasidenib (AG-221) counteracts the alterations induced by mutant IDH2 on DNA methylation in mutant stem/progenitor cells, fostering differentiation and inhibiting the self-renewal capabilities of IDH2-mutant leukemia cells. These effects are notably intensified when Flt3ITD is concurrently inhibited. Enasidenib therapy leads to leukemic cell differentiation, evidenced by an increased CD11b+ population and a decreased c-Kit+ population in the peripheral blood within 2 weeks[2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.78mL 1.76mL 0.88mL |
17.56mL 3.51mL 1.76mL |
参考文献 |
---|